AK MEDICAL (01789) has released its annual results for the period ending December 31, 2025. The group achieved revenue of RMB1.482 billion, representing an increase of 10.1% compared to the previous year. Profit attributable to the company's equity shareholders for the year was RMB339 million, a rise of 23.8% year-on-year. Basic earnings per share were RMB0.304, and the board has recommended a final dividend of 11.8 HK cents per share.

During 2025, driven by the volume-based procurement policy, the acceleration of import substitution continued. This led to sustained growth in demand for the number of procedures using the company's products. The rapid increase in surgical volumes, coupled with the contribution from the full-process digital orthopedic solutions, further enhanced the penetration rate of the company's products in hospitals and contributed to additional sales growth.

Furthermore, through active market expansion, the group saw significant growth in overseas revenue, as well as in its digital orthopedic intelligent products and services. The group's net profit for the year ended December 31, 2025, was RMB339 million, a notable increase of 23.8% compared to the same period in 2024. The significant profit growth was primarily attributable to the increase in revenue and an improvement in gross profit margin, driven by higher contributions from overseas sales and digital orthopedic customized products and services.